Hey, if you're planning to be in San Diego June 3, we've got a biotech event planned you should check out. I'll be chatting with Aviv Regev, Matt Gline and others.
endpts.com/trailblazers-i…

See you there! If you'll be attending in person, make sure to say hello to our team.

Big name, great chat ⌨️ with Siddhartha Mukherjee

NEW: I sat down (virtually) with biotech's Renaissance man, Siddhartha Mukherjee

We talked about AI, his slew of ambitious biotech startups, and how he got into writing epic, Pulitzer-winning tomes on medicine and science

The latest Endpoints News Slack edition:
endpts.com/the-endpoints-…

⚡️This Thurs: The FT/Endpoints US Pharma + Healthcare summit. Chats with:
* U.S. FDA's Tala Fakhouri on AI
* FTC's Rahul Rao on antitrust
* Biogen CEO Chris Viehbacher on everything
+ Ro CEO Z Reitano, Eikon Therapeutics CEO Roger Perlmutter, Lux Cap's Josh Wolfe
uspharma.live.ft.com/agenda

Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes. endpts.com/novo-clears-ph…

Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and payer interaction staff as it prepares for a potential launch. endpts.com/cytokinetics-l…

Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an updated draft of the closely watched Biosecure Act circulating ahead of the planned markup Wednesday. endpts.com/new-biosecure-…

Gene insertion and integration is the new vanguard of the gene editing field. At #ASGCT2024 this week, David R. Liu, Tome Biosciences, SalioGen Therapeutics, and Renegade Therapeutics all presented first looks at their new tools. Read more in my story for Endpoints News:

endpts.com/scientists-and…

As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the center of a bill targeting Chinese biotechs.

So I asked him about that in an interview.

endpts.com/bio-ceo-defend…

Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday. endpts.com/across-two-cli…

From yesterday:

House members want drugmakers to end their existing contracts with WuXi AppTec and other Chinese firms by 2032.

endpts.com/exclusive-lawm…

Shao-Lee Lin is stepping down as founding CEO of Acelyrin, a California drug developer that raised the largest biotech IPO in 2023 and subsequently ran into clinical hurdles with its lead immunology candidate. endpts.com/acelyrins-foun…

For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the market felt unimpeachable, with AbbVie’s Humira retaining 96% of the share by February. That changed when Humira came off the formulary of CVS Health’s pharmacy…

China was once zipping ahead of the US in clinical trials of #CRISPR therapies. The CRISPR baby scandal of 2018 stalled the country's progress. Now, a resurgence of gene editing trials are underway at Chinese biotechs. Read more in my article for Endpoints News:

endpts.com/after-crispr-b…

A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed. endpts.com/patient-dies-i…

Eli Lilly will face questions from a panel of Alzheimer’s experts on June 10, setting up an approval decision for donanemab after a surprise delay by the FDA in early March. endpts.com/lilly-gets-jun…

CMS is out with new guidance to limit industry meetings for next round (2027) of Medicare drug price negotiations - PhRMA and I Am Biotech are not happy endpts.com/industry-group…

Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye Zhou told Endpoints News. endpts.com/astrazeneca-al…